Karnataka | 15 January 2025 | News
JNCASR develops new system for wearable devices that can detect stress
Using silver wire network on a stretchable material, scientists fro...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 17 January 2025 | News
Medtech manufacturers hail CDSCO move on stopping import of used medical devices
Medical device manufacturers have hailed the clarification by the Central Drugs Standard Control Organization ...Read more
Karnataka | 17 January 2025 | News
CrisprBits opens Research and Innovation Centre for Gene Editing and Diagnostics in Bengaluru
Bengaluru-based biotechnology startup CrisprBits has inaugurated a CRISPR gene...Read more
Supplier | 09 January 2025 | News
Bruker launches infrared imaging microscope for pharma and life science research
US-based Bruker Corporation has announced the launch of the LUM...Read more
People | 09 January 2025 | News
Medanta appoints leading urologist Dr Sanjay Gogoi as Chairman of Renal Care Institute
Reinforcing its leadership in advanced kidney care and transplantation, Medanta has appointed globally renowne...Read more
Karnataka | 14 January 2025 | News
Tata Group and IISc partner to establish medical school to pioneer healthcare education
The Tata Group has announced a partnership with th...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations, led ...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com